

# Hansoh Pharmaceutical Group Company Limited翰森製藥集團有限公司 <br> （Incorporated in the Cayman Islands with limited liability） 

（Stock Code：3692）

## VOLUNTARY ANNOUNCEMENT

## DRUG REGISTRATION APPROVAL OF ＂CANAGLIFLOZIN TABLETS＂

The board of directors（the＂Board＂）of Hansoh Pharmaceutical Group Company Limited （the＂Company＂and together with its subsidiaries，the＂Group＂）is pleased to announce that ＂canagliflozin tablets＂，which is developed by Jiangsu Hansoh Pharmaceutical Group Co．，Ltd． （江蘇豪森藥業集團有限公司），a subsidiary of the Company，has been granted drug registration approval by the National Medical Products Administration of the People＇s Republic of China． Canagliflozin tablets has obtained approval for marketing and is the first sodium－glucose cotransporter 2 （SGLT－2）inhibitor produced in China，which is indicated for patients with type II diabetes．

Through inhibiting the re－absorption of glucose by renal tubules，canagliflozin tablets are able to reduce the level of glucose in blood so as to achieve the effect of treating patients with type II diabetes．As it is not dependent on insulin secretion and action，it is capable of having therapeutic effect on all patients with different stages of type II diabetes．

By Order of the Board<br>Hansoh Pharmaceutical Group Company Limited Zhong Huijuan<br>Chairlady

Hong Kong，December 24， 2019
As at the date of this announcement，the Board comprises Ms．Zhong Huijuan as chairlady and executive director，Mr．Lyu Aifeng and Miss Sun Yuan as executive directors，Ms．Ma Cuifang as non－executive director，and Mr．Lin Guoqiang，Mr．Chan Charles Sheung Wai and Ms．Yang Dongtao as independent non－executive directors．

